Autoantibodies to truncated GAD(96-585) antigen stratify risk of early insulin requirement in adult-onset diabetes.


Journal

Diabetes
ISSN: 1939-327X
Titre abrégé: Diabetes
Pays: United States
ID NLM: 0372763

Informations de publication

Date de publication:
08 Jul 2024
Historique:
received: 21 05 2024
accepted: 25 06 2024
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: aheadofprint

Résumé

We investigated whether characterisation of full-length (f-)GADA responses could identify early insulin requirement in adult-onset diabetes. In 179 f-GADA positive participants diagnosed with type 2 diabetes, we assessed associations of truncated (t-)GADA positivity, f-GADA IgG subclasses, and f-GADA affinity with early insulin requirement (<5 years), type 1 diabetes genetic risk score (T1D GRS), and C-peptide. t-GADA positivity was lower in f-GADA positive without early insulin in comparison to f-GADA positive type 2 diabetes requiring insulin within 5 years, and type 1 diabetes (75% vs. 91% and 95% respectively, p<0.0001). t-GADA positivity (in those f-GADA positive) identified a group with a higher type 1 diabetes genetic susceptibility (mean T1D GRS 0.248 vs. 0.225, p=0.003), lower C-peptide (1156 pmol/L vs. 4289 pmol/L, p=1x10-7), and increased IA-2A positivity (23% vs. 6%, p=0.03). In survival analysis, t-GADA positivity was associated with early insulin requirement compared with those only positive for f-GADA, independently from age of diagnosis, f-GADA titre and duration of diabetes [adjusted HR 5.7 (95% CI 1.4, 23.5), p=0.017]. The testing of t-GADA in f-GADA positive individuals with type 2 diabetes identifies those who have genetic and clinical characteristics comparable to type 1 diabetes and stratifies those at higher risk of early insulin requirement.

Identifiants

pubmed: 38976498
pii: 156953
doi: 10.2337/db23-0980
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the American Diabetes Association.

Auteurs

Sian L Grace (SL)

The Department of Biological and Clinical Science, University of Exeter Medical School, Exeter, U.K.
School of Translational Sciences, Bristol Medical School, University of Bristol, Bristol, U.K.

Kathleen M Gillespie (KM)

School of Translational Sciences, Bristol Medical School, University of Bristol, Bristol, U.K.

Claire L Williams (CL)

School of Translational Sciences, Bristol Medical School, University of Bristol, Bristol, U.K.

Vito Lampasona (V)

San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Peter Achenbach (P)

Institute of Diabetes Research, Helmholtz Munich, German Center for Environmental Health, Munich, Germany.
Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Forschergruppe Diabetes, Munich, Germany.

Ewan R Pearson (ER)

Biomedical Research Institute, University of Dundee, Dundee, U.K.

Alistair J K Williams (AJK)

School of Translational Sciences, Bristol Medical School, University of Bristol, Bristol, U.K.

Anna E Long (AE)

School of Translational Sciences, Bristol Medical School, University of Bristol, Bristol, U.K.

Timothy J McDonald (TJ)

The Department of Biological and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Academic Department of Clinical Biochemistry, Royal Devon and Exeter NHS Foundation Trust, Exeter, U.K.

Angus G Jones (AG)

The Department of Biological and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Macleod Diabetes and Endocrine Centre, Royal Devon and Exeter NHS Foundation Trust, Exeter, U.K.

Classifications MeSH